Novartis’ Tasigna and Bristol’s Sprycel Obtain Approval In Japan
This article was originally published in PharmAsia News
Executive Summary
Two drugs indicated to treat chronic myelocytic leukemia, Novartis' Tasigna (nilotinib) and Bristol-Myers Squibb's Sprycel (dasatinib) obtained approval in Japan. The drugs are used to treat patients resistant to Novartis' Glivec (imatinib). (Click here for more - Japanese language